We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Study Explains How Protein Complex Mediates T-cell Development

By Gerald M. Slutzky, PhD
Posted on 30 Nov 2016
A recent paper extended our understanding of how T-cells develop into critical components of the immune system that are able to fight off pathogens without going out of control and triggering an autoimmune response.

The linear ubiquitin chain assembly complex (LUBAC) is a protein complex that is essential for innate immunity in mice and humans, yet its role in adaptive immunity is unclear. More...
In an effort to better define the role of LUBAC, investigators at the Walter and Eliza Hall Institute (Melbourne, Australia) examined the requirement for each LUBAC component in T-cell and regulatory T-cell (Treg) cell lineages.

Results published in the November 18, 2016, online edition of the journal Nature Communications revealed that LUBAC components HOIP, HOIL-1, and SHARPIN played pivotal roles in late thymocyte differentiation of conventional T-cells, non-conventional T-cells and Treg cell homeostasis. LUBAC activity was necessary for the transcriptional programming of late thymocyte differentiation. LUBAC activity was not required to prevent TNF (tumor necrosis factor)-induced apoptosis or necroptosis but was necessary for the transcriptional program of the final stages of thymocyte differentiation.

"Another interesting aspect of this research relates to rare inherited immune disorders caused by defects in the genes that encode the components of LUBAC," said senior author Dr. Daniel Gray. "Our research has provided new insights into how these disorders are linked to faulty T-cell function. This may inspire to new immune-based therapies for these conditions. We hope that by understanding this process better, we may be able to develop new approaches to "switch off" autoimmune T-cells. This may have therapeutic applications in the future for treating autoimmune diseases."

Related Links:
Walter and Eliza Hall Institute


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Silver Member
Urine Test Strips
LabStrip U12 mALB/CREA
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.